SG11202104953VA - Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof - Google Patents

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Info

Publication number
SG11202104953VA
SG11202104953VA SG11202104953VA SG11202104953VA SG11202104953VA SG 11202104953V A SG11202104953V A SG 11202104953VA SG 11202104953V A SG11202104953V A SG 11202104953VA SG 11202104953V A SG11202104953V A SG 11202104953VA SG 11202104953V A SG11202104953V A SG 11202104953VA
Authority
SG
Singapore
Prior art keywords
fluorobenzyl
pyrazolo
pyrimidin
diamino
pyridin
Prior art date
Application number
SG11202104953VA
Other languages
English (en)
Inventor
Peter Fey
Michal Sowa
Joerg Brockob
Markus Longerich
Guido Becker
Heike Neumann
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of SG11202104953VA publication Critical patent/SG11202104953VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202104953VA 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof SG11202104953VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213115 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (fr) 2018-12-17 2019-12-16 Produit à base de composé actif de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate ayant des propriétés améliorées, production et formulations associées

Publications (1)

Publication Number Publication Date
SG11202104953VA true SG11202104953VA (en) 2021-06-29

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104953VA SG11202104953VA (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Country Status (18)

Country Link
US (1) US20220048907A1 (fr)
EP (1) EP3898624A1 (fr)
JP (1) JP2022515376A (fr)
KR (1) KR20210104703A (fr)
CN (1) CN113207290B (fr)
AR (1) AR116912A1 (fr)
AU (1) AU2019409269A1 (fr)
BR (1) BR112021009122A2 (fr)
CA (1) CA3123360A1 (fr)
CL (1) CL2021001580A1 (fr)
CO (1) CO2021007668A2 (fr)
IL (1) IL283976A (fr)
JO (1) JOP20210155A1 (fr)
MX (1) MX2021007090A (fr)
PE (1) PE20211593A1 (fr)
SG (1) SG11202104953VA (fr)
TW (1) TWI830835B (fr)
WO (1) WO2020126983A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169671A1 (fr) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations de carbamate de methyle {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (fr) 2020-06-16 2021-12-22 Adverio Pharma GmbH Procédé de préparation de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA3040720C (fr) * 2011-11-25 2021-06-15 Adverio Pharma Gmbh Procede de production de 5-fluoro-1h-pyrazolopyridines substituees
MX2015010725A (es) * 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
WO2016113415A1 (fr) * 2015-01-16 2016-07-21 Sandoz Ag Procédé de préparation de riociguat essentiellement exempt d'impuretés génotoxiques
WO2017025981A1 (fr) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Procédé de préparation de méthyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyle(méthyl)carbamate et de ses polymorphes
CA3169671A1 (fr) * 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations de carbamate de methyle {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (fr) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Procédé de préparation de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Also Published As

Publication number Publication date
PE20211593A1 (es) 2021-08-18
CN113207290A (zh) 2021-08-03
CL2021001580A1 (es) 2021-12-03
BR112021009122A2 (pt) 2021-08-10
KR20210104703A (ko) 2021-08-25
CN113207290B (zh) 2024-04-09
AR116912A1 (es) 2021-06-23
TWI830835B (zh) 2024-02-01
EP3898624A1 (fr) 2021-10-27
AU2019409269A1 (en) 2021-06-03
JP2022515376A (ja) 2022-02-18
CO2021007668A2 (es) 2021-07-19
MX2021007090A (es) 2021-08-11
US20220048907A1 (en) 2022-02-17
JOP20210155A1 (ar) 2023-01-30
WO2020126983A1 (fr) 2020-06-25
CA3123360A1 (fr) 2020-06-25
IL283976A (en) 2021-07-29
TW202039488A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
HRP20181785T1 (hr) Proces za pripremanje metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata za uporabu kao farmaceutski aktivnog sastojka
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
EP3577116A4 (fr) Dérivés de n-cycloalkyl/hétérocycloalkyle-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine en tant qu'agents thérapeutiques
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
IL281127A (en) Pyrazolo[3,4-B]pyridine compounds as inhibitors of TAM and MET kinases
HK1217488A1 (zh) -二氨基- -氟苄基 -吡唑并 吡啶- -基 嘧啶- -基}甲基氨基甲酸甲酯的形式
IL283976A (en) Methyl {6,4-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[4,3-b]pyridin-3-yl]pyrimidin-5-yl}carbamate Active compound product having Its improved properties, manufacture and formulation
NZ603800A (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
EP3546460A4 (fr) Composé pyrimido[5,4-b]indolizine ou pyrimido[5,4-b]pyrrolizine, son procédé de préparation et son utilisation
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PT3500571T (pt) Compostos de imidazo[1,2-a] piridina, composições que os compreendem, métodos para o uso no tratamento de doenças e seus métodos de preparação
IL219861A0 (en) Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound
LT3697784T (lt) Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui
IL226095A (en) History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them
EP3215510A4 (fr) Imidazo[1,5-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux
EP3250572A4 (fr) Composés d'imidazo[1,2-a]pyridin-2-ylamine substitués, compositions pharmaceutiques et leurs méthodes d'utilisation
IL275293A (en) Combined treatments that include administration of H1 - pyrazolo[4, 3-B]pyridines
IL275290A (en) Combined treatments that include administration of H1 - pyrazolo[4, 3-B]pyridines
EP3730492A4 (fr) Composé pyrazolo[1,5-a]pyrimidine substitué, composition pharmaceutique et utilisation associée
IL219712A0 (en) Novel solvates of methyl {4, 6 -diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b] pyridin - 3 - yl] pyrimidin - 5 -yl} carbamate
PT3774795T (pt) 4-(1h-imidazol-5-il)-1h-pirrolo[2,3-b]piridinas para utilização no tratamento de leucemias, linfomas e tumores sólidos
EP3997088A4 (fr) Dérivés de 4-(imidazo [l, 2-a] pyridine-3-yl)-n-(pyridinyl) pyrimidine-2-amine en tant qu'agents thérapeutiques
IL243739A0 (en) History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders
AU2017903305A0 (en) DERIVATIVES OF 4-(IMIDAZO[1,2-a]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES
IL271628A (en) A new salt of N-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1H -pyrazolo[3,4-H]quinazoline-3-carboxamide, its preparation and formulations containing it